| BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen |
| S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P MidCap 400 and Karman Holdings to Join S&P SmallCap 600 | NEW YORK, July 14, 2026 /PRNewswire/ -- S&P SmallCap 600 constituent BrightSpring Health Services Inc. (NASD: BTSG) will replace Chart Industries Inc. (NYSE: GTLS)... ► Artikel lesen |
| LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen |
| LifeStance Health Group, Inc.: LifeStance Reports First Quarter 2026 Results | SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial results... ► Artikel lesen |
| EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Fresenius Medical Care AG
Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act]... ► Artikel lesen |
| JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat FMC mit einem Kursziel von 32,30 Euro auf "Underweight" belassen. Die von der US-Gesundheitsbehörde CMS bekannt gegebenen Erstattungssätze für... ► Artikel lesen |
| UBS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Sell' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für FMC mit einem Kursziel von 36 Euro auf "Sell" belassen. Der Gegenwind für die Gewinnentwicklung im Jahr 2027 nehme zu, schrieb... ► Artikel lesen |